[In vitro modulation of the invasive and metastatic potentials of human hepatocellular carcinoma by interlukin-2].
OBJECTIVE
To investigate the effects of interlukin-2 (IL-2) on the in vitro invasiveness and the expression of several cell surface antigens related to invasive and metastatic potentials of human hepatocellular carcinoma (HCC) QGY-7701 cell line.


METHODS
QGY-7701 cells were incubated with high concentration of IL-2 or low concentration of IL-2 in different time. The expression of ICAM-1, CD(44) and HLA-I of the tumor cells was determined by fluorescence-activated cell sorter (FACS) analysis The tumor cell binding affinity to extracellular matrix components was measured by cell attachment assay. The degree of homotypic aggregation was quantified by cell aggregation assay.


RESULTS
IL-2 treatment exhibited enhanced expression of ICAM-1 (from 8.3% to 20.5% after high concentration of IL-2 treatment and 17.3% after low concentration of IL-2 treatment) and HLA-I (from 9.8% to 25.4% and 22.1%, respectively after high and low concentration of IL-2 treatment), suppression of CD(44) (from 26.4% to 12.5% and 11.6%, respectively) on HCC cell line and decreased binding affinity to type IV collagen (from 23.5% to 12.4%, 32.3% to 13.8%, 45.7% to 19.6% at 20 min, 40 min and 60 min, respectively after high concentration of IL-2 treatment, and 9.6%, 12.5% and 17.9%, respectively after low concentration of IL-2 treatment) and fibronectin (from 18.6% to 14.1%, 31.2% to 18.4%, 44.5% to 20.5% at 20 min, 40 min and 60 min, respectively after high concentration of IL-2 treatment, and 14.6%, 17.1% and 18.9%, respectively after low concentration of IL-2 treatment) and the degree of homotypic aggregation (from 58.3% to 26.5%, 85.4% to 37.6%, 88.6% to 42.3% at 20 min, 40 min and 60 min, respectively after high concentration of IL-2 treatment, and 25.0%, 36.4% and 42.6%, respectively after low concentration of IL-2 treatment)of HCC cells.


CONCLUSIONS
IL-2 may directly alter tumor properties associated with invasive and metastatic phenotypes of HCC cells, and can inhibit the invasive and metastatic potentials of HCC cells.
Peng
G
G
Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Pang
Z
Z
D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000556:secondary; D015870:Gene Expression / Q000187:drug effects*; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000473:pathology*; D009361:Neoplasm Invasiveness; D014407:Tumor Cells, Cultured
D015395:Histocompatibility Antigens Class I; D018960:Hyaluronan Receptors; D007376:Interleukin-2; D018799:Intercellular Adhesion Molecule-1